Author's response to reviews

Title: Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells

Authors:

Yun-Hee Lee (rhee_yun_hee@hotmail.com)
Soo-Jin Jeong (soojin_jeong@hotmail.com)
Hyo-Jeong Lee (oknice79@hotmail.com)
Hyo-Jung Lee (hyonice77@hotmail.com)
Wonil Koh (wkoh@khu.ac.kr)
Ji Hoon Jung (ijh3470@hotmail.com)
Sun-Hee Kim (sunny16ff@hotmail.com)
Sung-Hoon Kim (sungkim7@khu.ac.kr)

Version: 7 Date: 15 January 2012

Author's response to reviews: see over
Dear Dr. Jigisha Patel MRCP, PhD, Editor-in-Chief:

We thank for the valuable comments about our manuscript entitled, “Inhibition of JAK2/STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells (Manuscript ID 1158690452571707)”. According to the comments, our manuscript was revised point by point and the answers to the comments were provided as follows:

Reviewer: Alessandra Russo

- the manuscript entitled: "Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells”, was revised according referee comments and it is now acceptable for publication in “BioMed Central”.

(Response) Thanks!

Reviewer: Bharat B Aggarwal

1. Figure 3B and 3D, the impressive upregulation of SHP-1 mRNA by EP was observed in U266 cells (Fig. 3D), while there was no significant changes in protein expression of SHP-1 (Fig. 3B).

(Response) We have re-performed Western blotting for SHP-1. The new clear blot was added in Fig. 3B.

2. Authors misunderstood the previous comment #4 (How do the authors know that anti-angiogenic effect of EP is STAT3 driven?). The anti-angiogenic role EP by modulating STAT3 should be demonstrated by either using STAT3 siRNA or ChIP assay.

(Response) Thank you for your valuable comments. Despite STAT3 siRNA transfection assay with EP, unfortunately we couldn’t get solid result we expected, since co-treatment of STAT3 siRNA and EP was too toxic to the cells.

We sincerely hope that we addressed our reasonable responses to the concerns raised by two reviewers and look forward to receiving a good news from your journal.

Sincerely yours,

Sung-Hoon Kim, O.M.D., Ph.D.
Director of Cancer Preventive Material Development Research Center
College of Oriental Medicine, Kyung Hee University
1 Hoegi-dong, Dongdaemun-ku, Seoul 130-701, South Korea
E-mail: sungkim7@khu.ac.kr
Tel; +82-2-961-9233, Fax; +82-2-964-1064